Refine by MP, party, committee, province, or result type.

Results 31-45 of 82
Sort by relevance | Sorted by date: newest first / oldest first

Finance committee  I think the report deserves further analysis. What I'll do is write to you with the answer to that question.

October 20th, 2011Committee meeting

Russell Williams

Finance committee  But the overall package, I think, is in a good direction. It's now time for action.

October 20th, 2011Committee meeting

Russell Williams

Finance committee  I think we have to work very hard to increase equitable access to innovative medicines and vaccines across this country. I don't think a national plan is the way to do it, and I don't think it's the way you will be most effective. I do believe in a pan-Canadian approach, but I al

October 20th, 2011Committee meeting

Russell Williams

International Trade committee  Merci beaucoup. Thank you very much for the opportunity to appear today. I'm accompanied by Brigitte Nolet from Hoffmann-LaRoche Canada, one of our member companies, which has facilities in both Mississauga and Laval, and also Declan Hamill, our VP of legal affairs. Our indust

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  The sort of investment that Brigitte has just mentioned is the track record of our industry. Each time the government has moved forward, we have responded. In fact, changes in the Patent Act from 1987 have resulted in an increase of 1,500% in terms of R and D. Despite negative

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  I understood and received it that way, and if we need more time later on, we'll certainly get together. I appreciate the question, because we're all interested in trying to handle health care costs. I have to say, though, that the figure you were using is unfounded. It is based

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  I'll ask Brigitte to complement my answer. When companies decide where to invest and bring jobs, they consider a number of factors: infrastructure, quality of the research, access to the health care system, and a number of other factors. IP is one of them. The size of the mar

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  We've seen it being whittled away. It's a quiet death by a thousand cuts. Other research areas are getting it. We spend about $100 billion a year on research around the world. Every jurisdiction is absolutely doing its best to try to get it. When we try to win those contracts, we

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  We haven't seen it. What we are seeing is that as we are talking about creating a free trade environment, this is a golden opportunity for Canada to be in a privileged position to do that research that will save lives and improve our health care system. Here's an opportunity, wit

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  I will ask Declan to comment. We are saying there are a lot of discussions that aren't comparing apples with apples. There is a lot of misinformation. In fact, Norton Rose has just done an analysis, which we can table. There were 22 products studied, and for well over the majorit

October 27th, 2011Committee meeting

Russell Williams

International Trade committee  It's based on the fundamentally flawed premise that weak IP can be used to control health costs. A number of studies have shown that a lot of what they talk about has not come true. During the last 20 years, in the 1980s and in 2006, when the government has moved forward on data

October 27th, 2011Committee meeting

Russell Williams

Health committee  Merci beaucoup. Thank you, Madam Chair. Thank you, committee members, for the opportunity to appear before you today. As you mentioned, seated with me is Mark Ferdinand, our senior director of health and economic policy. He has been a key worker in terms of the working group

March 27th, 2012Committee meeting

Russell Williams

Health committee  I can at least begin. Thank you for asking this very complex question. You are quite right in saying that the solution...

March 27th, 2012Committee meeting

Russell Williams

Health committee  Thank you. With respect to your question about diversifying sources of supply, this morning I heard that HealthPRO was going to make a suggestion. Perhaps this may be a model that we could use. At the federal level, we have worked on the vaccination file in the past. That may of

March 27th, 2012Committee meeting

Russell Williams

Health committee  Thank you very much. I may have to meet you after this meeting in order to answer all of your questions. The cost of medication...

March 27th, 2012Committee meeting

Russell Williams